Drugs / MK-5823
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT01614782 | Jun → Oct 2012 | type 2 diabetes mellitus | Merck Sharp & Dohme LLC | Terminated | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | MK-5823 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT01614782 ↗ |
| Route | Subcutaneous | “MK-5823 administered subcutaneously” NCT01614782 ↗ |